Background: The goal of this study was to document the existence of psychological side effects associated with serotonin reuptake inhibitors (SSRIs) taken for depression and to determine their relationship to patients’ decisions to stop treatment, and attitudes toward taking SSRIs again. Method: We conducted 161 semi-structured telephone interviews of adults who had completed a course of treatment for depression with one of the SSRIs. We identified 29 categories of unwanted psychological effects and analyzed data in terms of responders and non-responders, the former split into those who would, and those who would not take the same drug again if depressed in the future (‘take-again responders’ and ‘not-again responders’, respectively). Results: Psychological side effects were cited just as often as physical side effects as the primary reason for quitting SSRI treatment. Non-responders cited psychological side effects rather than non-response as the primary reason for quitting, and not-again responders cited physical more than psychological side effects. Not-again responders and non-responders did not differ in the number of side effects experienced, and non-responders experienced significantly more unwanted psychological effects than either type of responder (χ2 = 6.767, p = 0.009). Conclusion: Psychological side effects might well be included in measures and discussions of side effects, even though they present no known physical danger to the patient.

Keywords:
Depressive disorder, drug therapy, Patient satisfaction, Serotonin reuptake inhibitors, therapeutic use, Serotonin reuptake inhibitors, adverse effects, Patient dropouts, psychology
1.
Basco MR, Rush JA: Compliance with pharmacotherapy in mood disorders. Psychiatr Ann 1995;25:269–279.
2.
Johnson DAW: Depression: Treatment compliance in general practice. Acta Psychiatr Scand 1981;63(suppl 290):447–453.
3.
Settle EC Jr: Antidepressant side effects: Issues and options. J Clin Psychiatry 1992;10:48–61.
4.
Engstrom FW: Clinical correlates of antidepressant compliance; in Cramer JA, Spiker B (eds): Compliance in Medical Practice and Clinical Trials. New York, Raven Press, 1991, pp 187–194.
5.
Kohlenberg RJ: FAP Enhanced Cognitive Therapy for Depression 1997–2000. NIMH MH53933-02.
6.
Lasalvia A, Ruggeri M, Santolini N: Subjective quality of life: Its relationship with clinician-rated and patient-rated psychopathology. Psychother Psychosom 2002;71:275–284.
7.
Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives. Psychother Psychosom 2000;69:184–197.
8.
Baldessarini RJ, Marsh E: Fluoxetine and side effects. Arch Gen Psychiatry 1990;47:191–192.
9.
Glenmullen J: Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants with Safe, Effective Alternatives. New York, Simon & Schuster, 2000.
10.
Hoehn-Saric R, Lipsey JR, McLeod DR: Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990;10:343–345.
11.
Settle EC Jr: Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998;59(suppl 16):25–30.
12.
Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, Paulsen JS, Litvan I: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314–319.
13.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1–99.
14.
Marin RS: Differential diagnosis and classification of apathy. Am J Psychiatry 1990;147:22–29.
15.
Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B: Apathy: A treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23–30.
16.
Hogan TP, Awad AG: Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychol Med 1992;22:347–352.
17.
Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983;13:177–183.
18.
Van Putten T, May PRA: Subjective response as a predictor of outcome in pharmacotherapy: The consumer has a point. Arch Gen Psychiatry 1978;35:477–480.
19.
Van Putten T, May PRA, Marder SR, Wittman LA: Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187–190.
20.
Lin EHB, Von Korff M, Katon W, Bush T, Simon GE, Walker E, Robinson P: The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 1995;33:67–74.
21.
Streiner DL, Norman GR: Health Measurement Scales: A Practical Guide to Their Development and Use, ed 2. New York, Oxford University Press, 1995, pp 116–122.
22.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DC, American Psychiatric Association, 1994.
23.
Bartlett FC: Remembering: A Study in Experimental and Social Psychology. New York, Macmillan, 1932.
24.
Zettle RD, Hayes SC: Dysfunctional control by client verbal behavior: The context of reason-giving. Anal Verb Behav 1986;4:30–38.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.